AOD‑9604 5mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of AOD-9604 supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025027

Key analytical results include:

• Assay Content: 5.39 mg
• Identification – Retention Time: 1.000
• Identification – Spectrum: 998
• Purity: 99.2 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone and is frequently studied in controlled laboratory environments investigating metabolic signalling pathways.

The compound belongs to a class of modified peptide fragments designed to explore biological signalling mechanisms associated with lipid metabolism and cellular energy regulation.

This preparation contains 5 mg of high purity lyophilized compound supplied in a sealed research vial. The lyophilization process preserves molecular stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide sequence and verified analytical profile, AOD-9604 has become a widely referenced compound in experimental metabolic research models.

Compound Overview

AOD-9604, also known as Anti-Obesity Drug 9604, is a modified peptide fragment derived from amino acids 176–191 of human growth hormone.

The compound was developed to study signalling pathways associated with lipid metabolism and adipose tissue regulation without reproducing the complete biological activity of full-length growth hormone.

Within biochemical research environments, peptide fragments such as AOD-9604 are utilised to investigate molecular signalling networks involved in metabolic regulation and cellular energy pathways.

The defined peptide structure allows researchers to examine receptor interaction behaviour and peptide-mediated signalling responses in controlled laboratory systems.

Historical Background and Scientific Context

Scientific interest in growth hormone fragments expanded during the late twentieth century as researchers began isolating specific peptide regions responsible for biological signalling effects.

During the 1990s and early 2000s, scientists investigated smaller peptide fragments capable of interacting selectively with metabolic regulatory pathways.

This research led to the identification of the growth hormone fragment 176–191, which later became the basis for the development of AOD-9604.

Since then the compound has been referenced in experimental metabolic research investigating peptide-mediated signalling and regulatory mechanisms.

Mechanistic Focus in Research

Within experimental laboratory settings, AOD-9604 is frequently studied in relation to peptide-mediated metabolic signalling pathways.

Research investigations commonly explore the compound in experimental models examining:

• Lipid metabolism signalling pathways
• Peptide-receptor interaction mechanisms
• Adipose tissue regulatory signalling systems
• Intracellular metabolic network modelling
• Cellular energy regulation pathways
• Comparative peptide fragment research
• Molecular metabolic signalling dynamics

These experimental models allow scientists to investigate molecular regulatory processes influencing metabolic signalling and biochemical pathway interactions.

Research Applications

In controlled research environments, AOD-9604 may be utilised in experimental models designed to explore peptide-mediated metabolic regulation and cellular signalling systems.

Examples of research applications include:

• Metabolic pathway investigation
• Peptide signalling analysis
• Adipose tissue regulatory research
• Molecular metabolic regulation studies
• Comparative peptide fragment evaluation
• Intracellular signalling network modelling
• Controlled in vitro metabolic studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Purity 99.2% with validated assay content 5.39 mg
• No detectable heavy metals or microbial contamination
• Endotoxin level below 0.001 EU per mg
• Batch GF082025027 – Published September 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.